Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Suresh K. Balani"'
Autor:
Sandeepraj Pusalkar, Swapan K. Chowdhury, Richard Czerniak, Xiaochun Zhu, Yuexian Li, Suresh K. Balani, Diane Ramsden
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 47:371-386
Autor:
Chunlin Chen, Liming Zhang, Cristina Almansa, Maria Rosario, Michael Cwik, Suresh K. Balani, Ruth Lock
Publikováno v:
Clinical Pharmacology in Drug Development. 11:142-149
Publikováno v:
Xenobiotica. :1-12
Trazpiroben (TAK-906), a peripherally selective dopamine D2/D3 receptor antagonist, is being developed for the treatment of patients with gastroparesis. The potential of trazpiroben to act as a perpetrator or a victim for cytochrome P450 (CYP)- or tr
Autor:
Cindy Q. Xia, Sandeepraj Pusalkar, Yuexian Li, Karthik Venkatakrishnan, Suresh K. Balani, Lawrence Cohen, Xiaofei Zhou, Wen Chyi Shyu, Jun Johnny Yang, Swapan Chowdhury, Chuang Lu
Publikováno v:
Drug Metabolism and Disposition. 48:217-229
Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies. This metabolic profiling analysis was conducted as part of a broa
Autor:
Sandeepraj, Pusalkar, Swapan K, Chowdhury, Richard, Czerniak, Xiaochun, Zhu, Yuexian, Li, Suresh K, Balani, Diane, Ramsden
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 47(3)
Felcisetrag (previously TAK-954 or TD-8954) is a highly selective and potent 5-HTThe metabolism and victim and perpetrator drug interaction potentials towards cytochrome P450s (CYP) and transporters were determined using in vitro models. The excretio
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 51(6)
Trazpiroben (TAK-906), a peripherally selective dopamine D2/D3 receptor antagonist, is being developed for the treatment of patients with gastroparesis. The potential of trazpiroben to act as a perpetrator or a victim for cytochrome P450 (CYP)- or tr
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:347-354
Monomethyl auristatin E (MMAE), the toxin linked to CD30-specific monoclonal antibody of Adcetris® (brentuximab vedotin), is a potent anti-microtubule agent. Brentuximab vedotin has been approved for the treatment of relapsed or refractory Hodgkin l
Autor:
Suresh K. Balani
Publikováno v:
Drug Metabolism Letters. 14:1-1
Autor:
Chunlin, Chen, Liming, Zhang, Cristina, Almansa, Maria, Rosario, Michael, Cwik, Suresh K, Balani, Ruth, Lock
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(2)
The 5-hydroxytryptamine type-4 receptor agonist felcisetrag (TAK-954) is being investigated for improving gastrointestinal motility in postoperative gastrointestinal dysfunction. Polypharmacy often occurs in this setting, and as in vitro data indicat
Autor:
Sandeepraj, Pusalkar, Xiaofei, Zhou, Yuexian, Li, Lawrence, Cohen, Jun Johnny, Yang, Suresh K, Balani, Cindy, Xia, Wen Chyi, Shyu, Chuang, Lu, Karthik, Venkatakrishnan, Swapan K, Chowdhury
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 48(3)
Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies. This metabolic profiling analysis was conducted as part of a broa